Article Text
Editorial
Adiponectin: an accurate biomarker for patients at risk for atrial fibrillation?
Statistics from Altmetric.com
Footnotes
Contributors ASB and JPP drafted and revised the editorial.
Competing interests JPP receives research funding from ARCA biopharma, Boston Scientific, Gilead, Janssen Pharmaceuticals, ResMed and St Jude Medical, and provides consulting to Johnson & Johnson, Laguna Pharmaceuticals, Medtronic and Spectranetics.
Provenance and peer review Commissioned; internally peer reviewed.
Linked Articles
- Arrhythmias and sudden death
- Heartbeat